To comprehensively evaluate the application prospect of serum piR-54265 as a novel and valuable CRC-specific biomarker, we have compared its ability in CRC detection or screening with some other serum tumor markers routinely used in clinic, including CEA, CA19-9 and CA125, and found that serum piR-54265 is much more sensitive than the other 3 markers. The gene discussed is CEACAM5; the disease is neoplasm.